DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9735ac/peptic_ulcer_pip) has announced the addition of Global Markets Direct's new report "Peptic Ulcer - Pipeline Review, H2 2011" to their offering.
'Peptic Ulcer - Pipeline Review, H2 2011', provides an overview of the Peptic Ulcer therapeutic pipeline. This report provides information on the therapeutic development for Peptic Ulcer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peptic Ulcer. 'Peptic Ulcer - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Peptic Ulcer.
- A review of the Peptic Ulcer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peptic Ulcer pipeline on the basis of route of administration and molecule type.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Peptic Ulcer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peptic Ulcer pipeline depth and focus of Peptic Ulcer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/9735ac/peptic_ulcer_pip